Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ICER 2020 Priorities Include Drugs For Ulcerative Colitis, NASH And Gene Therapies

Executive Summary

The Institute for Clinical and Economic Review has a full agenda planned for 2020, starting with potential new oral drugs for migraine.

You may also be interested in...



ICER Determines OCA’s Benefit In NASH Might Support Limited Approval

The cost-effectiveness watchdog group sees the fibrosis benefit with Intercept’s obeticholic acid as supporting use in sicker NASH patients, but its overall risk-benefit ratio doesn’t merit broader use.

Novartis CEO Explains Delay In Telling US FDA About Zolgensma Data Fraud: We Wanted To Understand It First

Novartis is in the process of "exiting" the "small number" of scientists involved in the fraud, CEO Narasimhan says.

Bluebird Pushes For Zynteglo Pricing Of Five €315K Annual Installments

CEO Nick Leschly talked to Scrip about the European payment strategy for the one-time gene therapy, which will cost €1.575m over five years if treatment is successful.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC125521

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel